Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice.
Identifieur interne : 000545 ( Ncbi/Merge ); précédent : 000544; suivant : 000546Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice.
Auteurs : Vince Pozsgay [États-Unis] ; Joanna Kubler-Kielb ; Rachel Schneerson ; John B. RobbinsSource :
- Proceedings of the National Academy of Sciences of the United States of America [ 0027-8424 ] ; 2007.
Descripteurs français
- KwdFr :
- MESH :
- biosynthèse : Antigènes O.
- génétique : Shigella dysenteriae.
- immunologie : Anticorps, Antigènes O, Shigella dysenteriae.
- sang : Anticorps.
- Animaux, Antigènes O, Bovins, Immunogénétique, Souris, Structure moléculaire.
English descriptors
- KwdEn :
- MESH :
- chemical , biosynthesis : O Antigens.
- chemical , blood : Antibodies.
- chemical , chemistry : O Antigens.
- chemical , classification : O Antigens.
- chemical , immunology : Antibodies, O Antigens.
- genetics : Shigella dysenteriae.
- immunology : Shigella dysenteriae.
- Animals, Cattle, Immunogenetics, Mice, Molecular Structure.
Abstract
Endemic and epidemic shigellosis, an acute invasive disease of the lower intestines, afflicts millions of people worldwide with an estimated one million fatalities per annum at a low infectious dose. Our approach to vaccine development against Shigella is based on the hypothesis that serum IgG antibodies to the O-specific polysaccharide (O-SP) domains of the LPS of these organisms confer protection to infection. The synthetic oligosaccharides corresponding to the tetrasaccharide repeating unit of the O-SP of Shigella dysenteriae type 1 covalently linked to human serum albumin elicited O-SP-specific IgG in mice. The antibody levels were a function of both the saccharide chain length and their loading on the protein. These synthetic saccharide conjugates elicited significantly higher levels of IgG anti O-SP than conjugates prepared with the O-SP from the bacteria. Here, we evaluated the influence of the nonreducing terminal monosaccharide on the serum antibody response. To this end, we prepared synthetic oligosaccharides comprising hexa- to tridecasaccharide fragments of the native O-SP, having one of the four monosaccharide residues that constitute the repeating unit at their termini and bound them to BSA by a single-point attachment. The conjugates contained an average of 19 saccharide chains per BSA. The synthetic oligosaccharides inhibited the binding of serum raised against whole bacteria to its LPS to a similar extent but lower than the native O-SP. The highest anti-LPS levels were elicited by conjugates having N-acetylglucosamine (10-mer) or galactose residues (7- and 11-mers) at their nonreducing termini.
DOI: 10.1073/pnas.0706969104
PubMed: 17726093
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002164
- to stream PubMed, to step Curation: 002164
- to stream PubMed, to step Checkpoint: 002066
Links to Exploration step
pubmed:17726093Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice.</title>
<author><name sortKey="Pozsgay, Vince" sort="Pozsgay, Vince" uniqKey="Pozsgay V" first="Vince" last="Pozsgay">Vince Pozsgay</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-2423, USA. pozsgayv@mail.nih.gov</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-2423</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kubler Kielb, Joanna" sort="Kubler Kielb, Joanna" uniqKey="Kubler Kielb J" first="Joanna" last="Kubler-Kielb">Joanna Kubler-Kielb</name>
</author>
<author><name sortKey="Schneerson, Rachel" sort="Schneerson, Rachel" uniqKey="Schneerson R" first="Rachel" last="Schneerson">Rachel Schneerson</name>
</author>
<author><name sortKey="Robbins, John B" sort="Robbins, John B" uniqKey="Robbins J" first="John B" last="Robbins">John B. Robbins</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2007">2007</date>
<idno type="RBID">pubmed:17726093</idno>
<idno type="pmid">17726093</idno>
<idno type="doi">10.1073/pnas.0706969104</idno>
<idno type="wicri:Area/PubMed/Corpus">002164</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002164</idno>
<idno type="wicri:Area/PubMed/Curation">002164</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002164</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002066</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002066</idno>
<idno type="wicri:Area/Ncbi/Merge">000545</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice.</title>
<author><name sortKey="Pozsgay, Vince" sort="Pozsgay, Vince" uniqKey="Pozsgay V" first="Vince" last="Pozsgay">Vince Pozsgay</name>
<affiliation wicri:level="2"><nlm:affiliation>Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-2423, USA. pozsgayv@mail.nih.gov</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-2423</wicri:regionArea>
<placeName><region type="state">Maryland</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kubler Kielb, Joanna" sort="Kubler Kielb, Joanna" uniqKey="Kubler Kielb J" first="Joanna" last="Kubler-Kielb">Joanna Kubler-Kielb</name>
</author>
<author><name sortKey="Schneerson, Rachel" sort="Schneerson, Rachel" uniqKey="Schneerson R" first="Rachel" last="Schneerson">Rachel Schneerson</name>
</author>
<author><name sortKey="Robbins, John B" sort="Robbins, John B" uniqKey="Robbins J" first="John B" last="Robbins">John B. Robbins</name>
</author>
</analytic>
<series><title level="j">Proceedings of the National Academy of Sciences of the United States of America</title>
<idno type="ISSN">0027-8424</idno>
<imprint><date when="2007" type="published">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antibodies (blood)</term>
<term>Antibodies (immunology)</term>
<term>Cattle</term>
<term>Immunogenetics</term>
<term>Mice</term>
<term>Molecular Structure</term>
<term>O Antigens (biosynthesis)</term>
<term>O Antigens (chemistry)</term>
<term>O Antigens (classification)</term>
<term>O Antigens (immunology)</term>
<term>Shigella dysenteriae (genetics)</term>
<term>Shigella dysenteriae (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Anticorps (immunologie)</term>
<term>Anticorps (sang)</term>
<term>Antigènes O ()</term>
<term>Antigènes O (biosynthèse)</term>
<term>Antigènes O (immunologie)</term>
<term>Bovins</term>
<term>Immunogénétique</term>
<term>Shigella dysenteriae (génétique)</term>
<term>Shigella dysenteriae (immunologie)</term>
<term>Souris</term>
<term>Structure moléculaire</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="biosynthesis" xml:lang="en"><term>O Antigens</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>O Antigens</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="classification" xml:lang="en"><term>O Antigens</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies</term>
<term>O Antigens</term>
</keywords>
<keywords scheme="MESH" qualifier="biosynthèse" xml:lang="fr"><term>Antigènes O</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Shigella dysenteriae</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Shigella dysenteriae</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps</term>
<term>Antigènes O</term>
<term>Shigella dysenteriae</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Shigella dysenteriae</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Cattle</term>
<term>Immunogenetics</term>
<term>Mice</term>
<term>Molecular Structure</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Antigènes O</term>
<term>Bovins</term>
<term>Immunogénétique</term>
<term>Souris</term>
<term>Structure moléculaire</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Endemic and epidemic shigellosis, an acute invasive disease of the lower intestines, afflicts millions of people worldwide with an estimated one million fatalities per annum at a low infectious dose. Our approach to vaccine development against Shigella is based on the hypothesis that serum IgG antibodies to the O-specific polysaccharide (O-SP) domains of the LPS of these organisms confer protection to infection. The synthetic oligosaccharides corresponding to the tetrasaccharide repeating unit of the O-SP of Shigella dysenteriae type 1 covalently linked to human serum albumin elicited O-SP-specific IgG in mice. The antibody levels were a function of both the saccharide chain length and their loading on the protein. These synthetic saccharide conjugates elicited significantly higher levels of IgG anti O-SP than conjugates prepared with the O-SP from the bacteria. Here, we evaluated the influence of the nonreducing terminal monosaccharide on the serum antibody response. To this end, we prepared synthetic oligosaccharides comprising hexa- to tridecasaccharide fragments of the native O-SP, having one of the four monosaccharide residues that constitute the repeating unit at their termini and bound them to BSA by a single-point attachment. The conjugates contained an average of 19 saccharide chains per BSA. The synthetic oligosaccharides inhibited the binding of serum raised against whole bacteria to its LPS to a similar extent but lower than the native O-SP. The highest anti-LPS levels were elicited by conjugates having N-acetylglucosamine (10-mer) or galactose residues (7- and 11-mers) at their nonreducing termini.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17726093</PMID>
<DateCompleted><Year>2007</Year>
<Month>10</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0027-8424</ISSN>
<JournalIssue CitedMedium="Print"><Volume>104</Volume>
<Issue>36</Issue>
<PubDate><Year>2007</Year>
<Month>Sep</Month>
<Day>04</Day>
</PubDate>
</JournalIssue>
<Title>Proceedings of the National Academy of Sciences of the United States of America</Title>
<ISOAbbreviation>Proc. Natl. Acad. Sci. U.S.A.</ISOAbbreviation>
</Journal>
<ArticleTitle>Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice.</ArticleTitle>
<Pagination><MedlinePgn>14478-82</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Endemic and epidemic shigellosis, an acute invasive disease of the lower intestines, afflicts millions of people worldwide with an estimated one million fatalities per annum at a low infectious dose. Our approach to vaccine development against Shigella is based on the hypothesis that serum IgG antibodies to the O-specific polysaccharide (O-SP) domains of the LPS of these organisms confer protection to infection. The synthetic oligosaccharides corresponding to the tetrasaccharide repeating unit of the O-SP of Shigella dysenteriae type 1 covalently linked to human serum albumin elicited O-SP-specific IgG in mice. The antibody levels were a function of both the saccharide chain length and their loading on the protein. These synthetic saccharide conjugates elicited significantly higher levels of IgG anti O-SP than conjugates prepared with the O-SP from the bacteria. Here, we evaluated the influence of the nonreducing terminal monosaccharide on the serum antibody response. To this end, we prepared synthetic oligosaccharides comprising hexa- to tridecasaccharide fragments of the native O-SP, having one of the four monosaccharide residues that constitute the repeating unit at their termini and bound them to BSA by a single-point attachment. The conjugates contained an average of 19 saccharide chains per BSA. The synthetic oligosaccharides inhibited the binding of serum raised against whole bacteria to its LPS to a similar extent but lower than the native O-SP. The highest anti-LPS levels were elicited by conjugates having N-acetylglucosamine (10-mer) or galactose residues (7- and 11-mers) at their nonreducing termini.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pozsgay</LastName>
<ForeName>Vince</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>Laboratory of Developmental and Molecular Immunity, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892-2423, USA. pozsgayv@mail.nih.gov</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kubler-Kielb</LastName>
<ForeName>Joanna</ForeName>
<Initials>J</Initials>
</Author>
<Author ValidYN="Y"><LastName>Schneerson</LastName>
<ForeName>Rachel</ForeName>
<Initials>R</Initials>
</Author>
<Author ValidYN="Y"><LastName>Robbins</LastName>
<ForeName>John B</ForeName>
<Initials>JB</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><Agency>Intramural NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052060">Research Support, N.I.H., Intramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2007</Year>
<Month>08</Month>
<Day>28</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Proc Natl Acad Sci U S A</MedlineTA>
<NlmUniqueID>7505876</NlmUniqueID>
<ISSNLinking>0027-8424</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000906">Antibodies</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019081">O Antigens</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002417" MajorTopicYN="N">Cattle</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007125" MajorTopicYN="Y">Immunogenetics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019081" MajorTopicYN="N">O Antigens</DescriptorName>
<QualifierName UI="Q000096" MajorTopicYN="N">biosynthesis</QualifierName>
<QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName>
<QualifierName UI="Q000145" MajorTopicYN="Y">classification</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012762" MajorTopicYN="N">Shigella dysenteriae</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year>
<Month>8</Month>
<Day>30</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2007</Year>
<Month>10</Month>
<Day>25</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2007</Year>
<Month>8</Month>
<Day>30</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">17726093</ArticleId>
<ArticleId IdType="pii">0706969104</ArticleId>
<ArticleId IdType="doi">10.1073/pnas.0706969104</ArticleId>
<ArticleId IdType="pmc">PMC1955462</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Vaccine. 2006 Feb 6;24(6):716-29</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16233938</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Immunol. 2006 Feb 1;176(3):1686-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16424198</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Org Chem. 2005 Aug 19;70(17):6987-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16095333</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Org Chem. 1998 Aug 21;63(17):5983-5999</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11672203</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bull World Health Organ. 1999;77(8):651-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10516787</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 1934 Oct 31;60(5):599-617</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19870325</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Carbohydr Res. 2006 Jul 24;341(10):1408-27</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16650395</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microbiology. 2007 Jan;153(Pt 1):139-47</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17185542</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioconjug Chem. 1991 Nov-Dec;2(6):458-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1805944</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microb Pathog. 1986 Jun;1(3):299-306</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2469932</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 1992 Aug;15(2):346-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1381621</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Biochem. 1993 Apr 1;213(1):573-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7682945</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2003 Nov;9(11):1471-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14718096</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Glycobiology. 2001 Nov;11(11):945-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11744629</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2004 Jul 23;305(5683):522-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15273395</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Exp Med. 1980 Aug 1;152(2):361-76</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6967514</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Biol Chem. 1993 Dec 5;268(34):25797-802</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7503987</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Endocrinol Metab. 1971 Dec;33(6):988-91</Citation>
<ArticleIdList><ArticleId IdType="pubmed">5316354</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Anal Biochem. 1986 May 15;155(1):95-102</Citation>
<ArticleIdList><ArticleId IdType="pubmed">3717562</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Carbohydr Res. 2006 Sep 4;341(12):2037-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16458277</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Bioconjug Chem. 1997 May-Jun;8(3):424-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9177850</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Microb Pathog. 1986 Jun;1(3):307-24</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2469933</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 Aug 30;362(9385):705-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12957094</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mol Immunol. 1996 Nov;33(16):1217-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9129157</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Biochem. 1976 Jul 15;66(3):559-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8314</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 1993 Sep;61(9):3678-87</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8359890</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 1999 Apr 27;96(9):5194-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10220442</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Immun. 1991 Dec;59(12):4450-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1937803</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Maryland</li>
</region>
</list>
<tree><noCountry><name sortKey="Kubler Kielb, Joanna" sort="Kubler Kielb, Joanna" uniqKey="Kubler Kielb J" first="Joanna" last="Kubler-Kielb">Joanna Kubler-Kielb</name>
<name sortKey="Robbins, John B" sort="Robbins, John B" uniqKey="Robbins J" first="John B" last="Robbins">John B. Robbins</name>
<name sortKey="Schneerson, Rachel" sort="Schneerson, Rachel" uniqKey="Schneerson R" first="Rachel" last="Schneerson">Rachel Schneerson</name>
</noCountry>
<country name="États-Unis"><region name="Maryland"><name sortKey="Pozsgay, Vince" sort="Pozsgay, Vince" uniqKey="Pozsgay V" first="Vince" last="Pozsgay">Vince Pozsgay</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000545 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000545 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= MersV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:17726093 |texte= Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:17726093" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a MersV1
This area was generated with Dilib version V0.6.33. |